ICAM4

Summary

ICAM4 (intercellular adhesion molecule 4 (Landsteiner-Wiener blood group), HGNC:5347) is a protein-coding gene on chromosome 19p13.2, encoding Intercellular adhesion molecule 4 (Q14773). Functions as a receptor ligand for the monocyte/macrophage-specific ITGAX:ITGB2 integrin complex and mediates erythrophagocytosis.

This gene encodes the Landsteiner-Wiener (LW) blood group antigen(s) that belongs to the immunoglobulin (Ig) superfamily, and that shares similarity with the intercellular adhesion molecule (ICAM) protein family. This ICAM protein contains 2 Ig-like C2-type domains and binds to the leukocyte adhesion LFA-1 protein. The molecular basis of the LW(A)/LW(B) blood group antigens is a single aa variation at position 100; Gln-100=LW(A) and Arg-100=LW(B). Alternative splicing results in multiple transcript variants encoding distinct isoforms.

Source: NCBI Gene 3386 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 58 total
• MANE Select transcript: NM_001544

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:5347
Approved symbol	ICAM4
Name	intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	CD242
Ensembl gene	ENSG00000105371
Ensembl biotype	protein_coding
OMIM	614088
Entrez	3386

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000340992, ENST00000380770, ENST00000393717, ENST00000929145

RefSeq mRNA: 2 — MANE Select: NM_001544 NM_001039132, NM_001544

CCDS: CCDS12232, CCDS32904

Canonical transcript exons

ENST00000380770 — 3 exons

Exon	Start	End
ENSE00001188319	10287536	10287838
ENSE00002843172	10286955	10287406
ENSE00002843212	10287986	10288520

Expression profiles

Bgee: expression breadth ubiquitous, 146 present calls, max score 80.06.

FANTOM5 (CAGE): breadth broad, TPM avg 2.4080 / max 138.9877, expressed in 578 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
173772	0.9537	171
173771	0.9497	348
173770	0.3716	157
173773	0.0698	36
173774	0.0633	30

Top tissues by expression

272 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.06	gold quality
monocyte	CL:0000576	78.09	gold quality
leukocyte	CL:0000738	77.54	gold quality
mononuclear cell	CL:0000842	77.46	gold quality
granulocyte	CL:0000094	76.48	gold quality
bone marrow	UBERON:0002371	74.07	gold quality
stromal cell of endometrium	CL:0002255	73.07	gold quality
blood	UBERON:0000178	72.27	gold quality
right lung	UBERON:0002167	71.56	gold quality
amniotic fluid	UBERON:0000173	70.67	gold quality
bone marrow cell	CL:0002092	70.02	silver quality
sperm	CL:0000019	69.78	silver quality
male germ cell	CL:0000015	68.25	silver quality
trabecular bone tissue	UBERON:0002483	67.45	gold quality
upper lobe of left lung	UBERON:0008952	66.27	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	65.37	gold quality
upper lobe of lung	UBERON:0008948	64.94	gold quality
lung	UBERON:0002048	64.78	gold quality
periodontal ligament	UBERON:0008266	60.70	gold quality
visceral pleura	UBERON:0002401	59.09	gold quality
pylorus	UBERON:0001166	58.87	gold quality
saphenous vein	UBERON:0007318	58.87	gold quality
inferior vagus X ganglion	UBERON:0005363	58.77	gold quality
pericardium	UBERON:0002407	58.68	gold quality
nipple	UBERON:0002030	58.35	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	58.26	gold quality
trigeminal ganglion	UBERON:0001675	58.20	gold quality
synovial joint	UBERON:0002217	58.19	gold quality
cartilage tissue	UBERON:0002418	58.11	silver quality
pons	UBERON:0000988	58.07	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-HCAD-6	yes	47.77
E-HCAD-10	no	2.39
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GATA2

miRNA regulators (miRDB)

13 targeting ICAM4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-4437	99.52	65.29	1266
HSA-MIR-671-5P	99.52	67.11	1277
HSA-MIR-12131	99.48	68.72	1673
HSA-MIR-223-5P	99.24	68.82	1206
HSA-MIR-6749-3P	99.00	65.73	1443
HSA-MIR-153-3P	98.96	72.51	1644
HSA-MIR-2355-5P	98.83	65.51	1589
HSA-MIR-4691-3P	98.11	66.83	1204
HSA-MIR-6881-3P	98.04	68.24	1777
HSA-MIR-4671-5P	97.10	65.70	93

Literature-anchored findings (GeneRIF, showing 18)

• ICAM-4 as the first red blood cells protein ligand of platelets that may have relevant physiological significance (PMID:12477717)
• binds to the I domains of the CD11a/CD18 and CD11b/CD18 leukocyte integrins (PMID:12694184)
• 12 single amino-acid changes in ICAM4 affected the interaction of ICAM-4 with alpha(V) integrins (PMID:14551135)
• LW on sickle but not on normal erythrocytes undergoes increased PKA-dependent serine phosphorylation as a result of activation. The major counter receptor for LW was identified as the alphavbeta3 integrin on ECs (PMID:15308566)
• Different integrins bind to different but partly overlapping sites on ICAM4, and ICAM4 may accommodate multiple integrin receptors present on leukocytes, platelets and endothelial cells. (PMID:15355350)
• Review. LW antigen contributes to RBC adhesion, thrombosis, and (in sickle cell disease) vaso-occlusion. (PMID:16564726)
• We show that ICAM-4 functions as a ligand for the monocyte/macrophage-specific CD11c/CD18. Deletion of the individual immunoglobulin domains of ICAM-4 demonstrated that both its domains contain binding sites for CD11c/CD18. (PMID:16985175)
• LW play potentially pathophysiological roles in sickle cell disease (PMID:17609430)
• LWa allele occurs with incidence of 100% of donors in this study, while LWb allele has not been found in Chinese population. (PMID:18549656)
• In a transgenic mouse model of sickle cell disease ICAM-4 is implicated in abnormal adhesiveness of erythrocytes to endothelium. (PMID:20015873)
• Erythrocyte plasma membrane-bound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium. (PMID:22147898)
• Data from differentiating cultured erythroid precursor cells suggest that RhAG (Rh-associated glycoprotein) knockdown abolishes Rh blood group expression (ICAM4; RhoD [ras homolog family member D]; CD47 Rh-related antigen) in erythroid cells. (PMID:23417980)
• Seven variant ICAM4 alleles were found, distinct from the wild-type ICAM4 allele (GenBank KF712272), known as LW*05 and encoding LW(a) . (PMID:24673173)
• ICAM-1 and ICAM-4 play roles in host cell invasion by M. tuberculosis and P. falciparum, respectively. (PMID:25586702)
• Cytometry analysis evidenced a specific expression profile on reticulocytes of SCA infants, with notably an increased expression of the adhesion molecules Lu/BCAM, ICAM-4 and LFA-3, both in percentage of positive cells and in surface density. (PMID:26137540)
• the effect of modulation of the cAMP-PKA-dependent pathway on ICAM-4 receptor activation (PMID:28076805)
• Immunological Study of IFN-gamma, ICAM-4, and Vitamin D3 Markers among Gastrointestinal Tumor Patients in Babylon Province, Iraq. (PMID:36708580)
• DNA methylation of ICAM4 and NOXO1 participate in the formation of uterine fibroids via regulating immune cell infiltration. (PMID:38015525)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Icam4	ENSMUSG00000001014
rattus_norvegicus	Icam4	ENSRNOG00000042078

Paralogs (4): ICAM3 (ENSG00000076662), ICAM1 (ENSG00000090339), ICAM5 (ENSG00000105376), ICAM2 (ENSG00000108622)

Protein

Protein identifiers

Intercellular adhesion molecule 4 — Q14773 (reviewed: Q14773)

Alternative names: Landsteiner-Wiener blood group glycoprotein

All UniProt accessions (2): Q14773, U5U6P8

UniProt curated annotations — full annotation on UniProt →

Function. Functions as a receptor ligand for the monocyte/macrophage-specific ITGAX:ITGB2 integrin complex and mediates erythrophagocytosis. Receptor ligand of the platelet-specific ITGA2B:ITGB3 integrin complex involved in heterotypic cell-cell adhesion between erythrocytes and activated platelets. In vitro, is also a receptor ligand of multiple integrin receptors complexes such ITGAL:ITGB2, ITGAM:ITGB2, ITGA5:ITGB1, ITGA5:ITGB3 and ITGA5:ITGB5 integrin complexes.

Subcellular location. Cell membrane Secreted Cell membrane.

Tissue specificity. Erythrocytes.

Post-translational modifications. N- and O-glycosylated.

Polymorphism. Responsible for the Landsteiner-Wiener blood group system [MIM:111250]. The molecular basis of the LW(A)=LW5/LW(B)=LW7 blood group antigens is a single variation in position 100; Gln-100 corresponds to LW(A) and Arg-100 to LW(B).

Similarity. Belongs to the immunoglobulin superfamily. ICAM family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q14773-1	Long	yes
Q14773-2	Short
Q14773-3	3

RefSeq proteins (2): NP_001034221, NP_001535* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003987	ICAM_VCAM_N	Domain
IPR013768	ICAM_N	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR047012	ICAM_VCAM	Family

Pfam: PF03921

UniProt features (20 total): glycosylation site 4, disulfide bond 4, splice variant 2, sequence variant 2, topological domain 2, domain 2, signal peptide 1, chain 1, sequence conflict 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14773-F1	83.83	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (4): 69–117, 69–113, 73–117, 153–210

Glycosylation sites (4): 223, 68, 78, 190

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-216083	Integrin cell surface interactions

MSigDB gene sets: 139 (showing top): VERHAAK_AML_WITH_NPM1_MUTATED_DN, BENPORATH_ES_WITH_H3K27ME3, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, MODULE_64, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOBP_VESICLE_MEDIATED_TRANSPORT, AAAYRNCTG_UNKNOWN, GNF2_ANK1, GOBP_CELL_CELL_ADHESION, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A4, GATA1_04, GFI1_01, GOBP_LEUKOCYTE_CELL_CELL_ADHESION, GOBP_CELL_ADHESION_MEDIATED_BY_INTEGRIN, GOMF_SIGNALING_RECEPTOR_BINDING

GO Biological Process (6): phagocytosis (GO:0006909), cell adhesion (GO:0007155), leukocyte cell-cell adhesion (GO:0007159), cell-cell adhesion mediated by integrin (GO:0033631), heterotypic cell-cell adhesion (GO:0034113), cell-cell adhesion (GO:0098609)

GO Molecular Function (3): integrin binding (GO:0005178), receptor ligand activity (GO:0048018), protein binding (GO:0005515)

GO Cellular Component (3): extracellular region (GO:0005576), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Adaptive Immune System	1
Extracellular matrix organization	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell-cell adhesion	3
signaling receptor binding	2
cellular anatomical structure	2
endocytosis	1
cellular process	1
cell adhesion mediated by integrin	1
cell adhesion	1
protein-containing complex binding	1
cell adhesion molecule binding	1
signal transduction	1
signaling receptor activator activity	1
binding	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

452 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ICAM4	ITGB2	P05107	965
ICAM4	ICAM1	P05362	788
ICAM4	ICAM2	P13598	740
ICAM4	MAEA	Q7L5Y9	734
ICAM4	GYPB	P06028	723
ICAM4	ITGAL	P20701	721
ICAM4	VCAM1	P19320	645
ICAM4	GYPA	P02724	638
ICAM4	BCAM	P50895	581
ICAM4	ITGAV	P06756	550
ICAM4	ITGA2B	P08514	539
ICAM4	ITGA4	P13612	533
ICAM4	CD47	Q08722	503
ICAM4	ITGAX	P20702	488
ICAM4	SIGLEC1	Q9BZZ2	481

IntAct

23 interactions, top by confidence:

A	B	Type	Score
SLC4A1	FLOT1	psi-mi:“MI:0914”(association)	0.530
CREB3	ICAM4	psi-mi:“MI:0915”(physical association)	0.370
IGHG1	PDPK1	psi-mi:“MI:0914”(association)	0.350
AQP1	FLOT1	psi-mi:“MI:0914”(association)	0.350
CHRNA4	TMEM223	psi-mi:“MI:0914”(association)	0.350
PDGFRA	GXYLT2	psi-mi:“MI:0914”(association)	0.350
MPPE1	FAM234B	psi-mi:“MI:0914”(association)	0.350
CHRNB2	TMEM131L	psi-mi:“MI:0914”(association)	0.350
CCL3	KRBA1	psi-mi:“MI:0914”(association)	0.350
SCN4A	C2CD4B	psi-mi:“MI:0914”(association)	0.350
CHRNB4	GPR89A	psi-mi:“MI:0914”(association)	0.350
SLC5A4	GPR89A	psi-mi:“MI:0914”(association)	0.350
C1QTNF7	AGRN	psi-mi:“MI:0914”(association)	0.350
HFE	PODXL	psi-mi:“MI:0914”(association)	0.350
CHRNE	PODXL	psi-mi:“MI:0914”(association)	0.350
NHLRC3	OGG1	psi-mi:“MI:0914”(association)	0.350
ICAM4	ATE1	psi-mi:“MI:0914”(association)	0.350
CDH16	EGFR	psi-mi:“MI:0914”(association)	0.350
TMEM106B	ICAM4	psi-mi:“MI:0914”(association)	0.350
ICAM4	ANKRD28	psi-mi:“MI:0914”(association)	0.350

BioGRID (42): KRT31 (Two-hybrid), NOTCH2NL (Two-hybrid), ICAM4 (Two-hybrid), ICAM4 (Affinity Capture-MS), ICAM4 (Two-hybrid), KRT34 (Two-hybrid), MTUS2 (Two-hybrid), CYSRT1 (Two-hybrid), NOTCH2NL (Two-hybrid), NBPF19 (Two-hybrid), DPP8 (Affinity Capture-MS), ICAM4 (Affinity Capture-MS), ICAM4 (Affinity Capture-MS), ICAM4 (Affinity Capture-MS), TOP3A (Affinity Capture-MS)

ESM2 similar proteins: A0A140LHF2, A0EQL2, D3YZF7, D7PDD4, O15533, O55237, O70394, O70540, O95866, P04278, P05111, P07994, P08689, P0C6B3, P0DP72, P15196, P17490, P18627, P40238, P55101, P60882, P97497, Q00657, Q08351, Q14393, Q14773, Q16671, Q3SWY4, Q5BK54, Q5NKT8, Q5TJE4, Q61790, Q61826, Q62588, Q6PZD2, Q6UVK1, Q6UWB1, Q7Z7M0, Q7Z7M1, Q86VR7

Diamond homologs: P05362, P13597, P13598, P32942, P33729, P35330, Q00238, Q14773, Q28125, Q28730, Q28806, Q5NKT8, Q5NKU6, Q5NKV1, Q5NKV2, Q5NKV4, Q5NKV6, Q5NKV9, Q60625, Q95132, Q9UMF0, Q9ERM2

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ICAM4	“form complex”	“Ankyrin complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 33 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of cell migration	5	11.0×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

58 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	40
Likely benign	13
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

328 predictions. Top by Δscore:

Variant	Effect	Δscore
19:10287407:G:GG	donor_gain	1.0000
19:10287369:A:T	donor_gain	0.9900
19:10287393:G:GT	donor_gain	0.9900
19:10287413:G:T	donor_gain	0.9900
19:10287418:GGGC:G	donor_gain	0.9900
19:10287800:T:TA	donor_gain	0.9900
19:10287801:G:GA	donor_gain	0.9900
19:10287834:GCTCG:G	donor_gain	0.9900
19:10287368:G:GT	donor_gain	0.9800
19:10287534:A:AG	acceptor_gain	0.9800
19:10287535:G:GG	acceptor_gain	0.9800
19:10287836:TCGGT:T	donor_loss	0.9800
19:10287837:CGGTG:C	donor_loss	0.9800
19:10287838:GGTGA:G	donor_loss	0.9800
19:10287839:G:GG	donor_gain	0.9800
19:10287839:G:T	donor_loss	0.9800
19:10287840:T:G	donor_loss	0.9800
19:10287412:G:GT	donor_gain	0.9700
19:10287535:GAACC:G	acceptor_gain	0.9700
19:10287533:TAGAA:T	acceptor_gain	0.9600
19:10287419:G:T	donor_gain	0.9500
19:10287534:AGAAC:A	acceptor_gain	0.9400
19:10287841:G:GG	donor_loss	0.9400
19:10287276:C:T	donor_gain	0.9300
19:10287531:CTTA:C	acceptor_loss	0.9200
19:10287532:TTA:T	acceptor_loss	0.9200
19:10287533:TAG:T	acceptor_loss	0.9200
19:10287534:AGA:A	acceptor_loss	0.9200
19:10287528:T:A	acceptor_loss	0.9100
19:10287984:A:AG	acceptor_gain	0.9000

AlphaMissense

1722 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:10287300:G:C	W96C	0.985
19:10287300:G:T	W96C	0.985
19:10287333:G:C	W107C	0.985
19:10287333:G:T	W107C	0.985
19:10287598:T:A	C153S	0.985
19:10287599:G:C	C153S	0.985
19:10287616:T:C	F159L	0.984
19:10287618:C:A	F159L	0.984
19:10287618:C:G	F159L	0.984
19:10287769:T:A	C210S	0.980
19:10287770:G:C	C210S	0.980
19:10287217:T:A	C69S	0.977
19:10287218:G:C	C69S	0.977
19:10287598:T:C	C153R	0.972
19:10287349:T:A	C113S	0.971
19:10287350:G:C	C113S	0.971
19:10287771:C:G	C210W	0.969
19:10287395:T:C	I128T	0.968
19:10287770:G:A	C210Y	0.968
19:10287154:T:C	F48L	0.967
19:10287156:C:A	F48L	0.967
19:10287156:C:G	F48L	0.967
19:10287395:T:G	I128S	0.963
19:10287617:T:G	F159C	0.962
19:10287769:T:C	C210R	0.960
19:10287351:C:G	C113W	0.959
19:10287230:G:A	C73Y	0.954
19:10287600:C:G	C153W	0.954
19:10287229:T:A	C73S	0.953
19:10287230:G:C	C73S	0.953

dbSNP variants (sampled 300 via entrez): RS1000675984 (19:10285576 G>A,C), RS1001130557 (19:10285254 C>T), RS1002288516 (19:10285542 T>C), RS1002582178 (19:10285907 C>T), RS1002689661 (19:10289004 G>T), RS1002757098 (19:10286874 T>C,G), RS1004185068 (19:10288469 A>C,T), RS1004301233 (19:10288265 T>A), RS1005716286 (19:10286881 C>A,T), RS1006799920 (19:10287128 T>G), RS1007262846 (19:10288821 G>A), RS1007326993 (19:10287392 G>A,T), RS1008880702 (19:10288522 C>T), RS1009280661 (19:10285588 G>A,T), RS1009447932 (19:10285405 G>A,C)

Disease associations

OMIM: gene MIM:614088 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006585_673	Blood protein levels	2.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression	4
Valproic Acid	affects expression, increases expression, increases methylation	4
Cyclosporine	decreases expression, increases expression	3
Aflatoxin B1	increases expression, affects expression	3
bisphenol A	increases expression, affects cotreatment, increases methylation	2
entinostat	increases expression, affects cotreatment	2
Tetrachlorodibenzodioxin	decreases expression, affects expression	2
dicrotophos	decreases expression	1
propionaldehyde	increases expression	1
butyraldehyde	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Aripiprazole	increases expression, affects cotreatment	1
Sunitinib	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Acetaminophen	increases expression	1
Demecolcine	increases expression	1
Doxorubicin	increases expression	1
Formaldehyde	increases expression	1
Hydrogen Peroxide	affects cotreatment, decreases expression	1
Lipopolysaccharides	increases expression, affects response to substance	1
Ozone	affects cotreatment, increases expression	1
Quercetin	increases expression	1
Silicon Dioxide	increases expression	1
Smoke	affects expression	1
Theophylline	affects cotreatment, decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.